Bloodworks Northwest
Seattle, Washington, 98104, United States
NCT Number: NCT02223117
This "first-in-human" exploratory IND, single-center study will assess the safety, toxicity, hematology, and immunogenicity of sub-therapeutic "microdoses" of autologous Thrombosomes® in healthy human subjects.
Looking for future studies?
Notify Me18 year–45 year
All sexes
Interventional
Early Phase 1
Seattle, Washington, 98104, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Freeze-dried platelets
Other names: Buffer/placebo Control
Time frame: 60 days
Time frame: 60 Days
Cellphire Therapeutics, Inc.
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07629414
Healthy, Heat Stress Disorders
Shreveport, Louisiana, United States
View Trial DetailsNCT07531628
Healthy
Hangzhou, China
View Trial DetailsNCT01866852
Healthy
Bethesda, Maryland, United States
View Trial DetailsNCT06354686
Healthy
Tallahassee, Florida, United States
View Trial Details